Wirth Discusses SELECT Trial: Lenvatinib in RAI-Refractory DTC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
targetedonc.com
Wirth Discusses SELECT Trial: Lenvatinib in RAI-Refractory DTC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Lori J. Wirth, MD, discusses the background and design of the phase 3 SELECT trial of lenvatinib vs placebo for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer.
May 1, 2024
Related Products
Belzutifan Lenvatinib
Celon Lenvatinib
Dicoumarol Lenvatinib
#Lenvatinib Uses
Primary Results from the Phase 3 Leap-002 Study: Lenvatinib plus Pembrolizumab versus Lenvatinib as First-Line Therapy for Advanced Hepatocellular Carcinoma | OncLive
Primary Results from the Phase 3 Leap-002 Study: Lenvatinib plus Pembrolizumab versus Lenvatinib as First-Line Therapy for Advanced Hepatocellular Carcinoma | OncLive
onclive.comSep 29, 2022
KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer | OncLive
KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer | OncLive
onclive.comAug 3, 2023
Top videos
The Evolving Role of Lenvatinib in the HCC Therapeutic Landscape | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
The Evolving Role of Lenvatinib in the HCC Therapeutic Landscape | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
targetedonc.com
Apr 3, 2025
Gemcitabine-Oxaliplatin-Lenvatinib (GEMOX-LEN) For Unresectable Fibrolamellar Carcinoma: Promising Results in First 16 Patients - Fibrolamellar Cancer Foundation
Gemcitabine-Oxaliplatin-Lenvatinib (GEMOX-LEN) For Unresectable Fibrolamellar Carcinoma: Promising Results in First 16 Patients - Fibrolamellar Cancer Foundation
fibrofoundation.org
2 months ago
Dr. Feldman on Lenvatinib and Pembrolizumab Plus Chemotherapy in NSCLC | OncLive
Dr. Feldman on Lenvatinib and Pembrolizumab Plus Chemotherapy in NSCLC | OncLive
onclive.com
May 23, 2022
Lenvatinib Side Effects
Dr. Martins on Managing Toxicities Associated With Lenvatinib in DTC | OncLive
Dr. Martins on Managing Toxicities Associated With Lenvatinib in DTC | OncLive
onclive.com
Feb 25, 2016
Decoding Lenvima: Unveiling its Mechanism of Action, Uses, and Potential Side Effects
9:43
Decoding Lenvima: Unveiling its Mechanism of Action, Uses, and Potential Side Effects
YouTubeInevid
3.8K viewsSep 11, 2023
Managing Adverse Reactions That May Occur with LENVIMA® (lenvatinib) in Patients with uHCC
21:53
Managing Adverse Reactions That May Occur with LENVIMA® (lenvatinib) in Patients with uHCC
YouTubeLENVIMA® (lenvatinib) HCP
59.8K viewsJan 7, 2025
The Evolving Role of Lenvatinib in the HCC Therapeutic Landscape | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
The Evolving Role of Lenvatinib in the HCC Therapeutic Landscape | …
Apr 3, 2025
targetedonc.com
Gemcitabine-Oxaliplatin-Lenvatinib (GEMOX-LEN) For Unresectable Fibrolamellar Carcinoma: Promising Results in First 16 Patients - Fibrolamellar Cancer Foundation
Gemcitabine-Oxaliplatin-Lenvatinib (GEMOX-LEN) For Unresectable Fi…
2 months ago
fibrofoundation.org
Dr. Feldman on Lenvatinib and Pembrolizumab Plus Chemotherapy in NSCLC | OncLive
Dr. Feldman on Lenvatinib and Pembrolizumab Plus Chemothera…
May 23, 2022
onclive.com
Study Results: Lenvatinib in Renal Cell Carcinoma | OncLive
Study Results: Lenvatinib in Renal Cell Carcinoma | OncLive
Jan 29, 2016
onclive.com
Lenvatinib/Pembrolizumab in RCC: Dosing and Adverse Event Management | OncLive
Lenvatinib/Pembrolizumab in RCC: Dosing and Adverse Event Manag…
Apr 1, 2022
onclive.com
Dr. Cheng on Phase III Findings of Lenvatinib in HCC | OncLive
Dr. Cheng on Phase III Findings of Lenvatinib in HCC | OncLive
Jun 26, 2017
onclive.com
Lenvatinib Pembrolizumab as Frontline Therapy for Advanced Renal Cell Carcinoma | OncLive
Lenvatinib Pembrolizumab as Frontline Therapy for Advanced R…
Mar 7, 2022
onclive.com
TACE Lenvatinib, Pembrolizumab Tied to Improved Survival in Unre…
267 viewsJan 15, 2025
diabetesincontrol.com
Lenvatinib in Metastatic Renal Cell Carcinoma | OncLive
Dec 19, 2015
onclive.com
Metastatic CRC: Pembrolizumab Plus Lenvatinib | OncLive
Aug 17, 2021
onclive.com
Dr. Finn on Considerations for Lenvatinib in Liver Cancer | OncLive
Sep 19, 2018
onclive.com
Primary Results from the Phase 3 Leap-002 Study: Lenvatinib plus P…
Sep 29, 2022
onclive.com
Lenvatinib - Alchetron, The Free Social Encyclopedia
Aug 8, 2015
alchetron.com
Nivolumab plus ipilimumab vs. Lenvatinib or sorafebib as first-lin…
2 months ago
onclive.com
Lenvatinib Plus Pembrolizumab in Endometrial Cancer After Neoadju…
3 months ago
targetedonc.com
3:52
LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With R…
Mar 8, 2024
onclive.com
Eisai Settles US Patent Dispute With Dr. Reddy's Over Lenvatinib
6 months ago
marketscreener.com
Approval of Lenvatinib: More Options | OncLive
Mar 4, 2015
onclive.com
EMERALD-3: tremelimumab durvalumab with or without lenvat…
Sep 10, 2022
vjoncology.com
Endometrial Cancer: Toxicity Management and Treatment Persi…
3 months ago
onclive.com
Next Steps With Pembrolizumab/Lenvatinib in End…
Apr 15, 2024
onclive.com
Dr. Cabanillas on Lenvatinib as First-Line Therapy for Patients Wi…
Feb 20, 2016
onclive.com
Lenvima (lenvatinib) mellékhatások, interakciók, felhasználások és gyó…
Aug 21, 2019
oldmedic.com
Dr. Armaghany on Frontline Sorafenib Versus Lenvatinib in Un…
Apr 4, 2020
onclive.com
4:27
Lenvatinib in Renal Cell Carcinoma
626 viewsFeb 24, 2016
YouTubeOncLive
KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Advanced Endo…
Aug 3, 2023
onclive.com
0:05
Experiences and Thoughts on Lenvatinib for Cancer
7.9K views11 months ago
TikTokjasonkara
0:59
Dr. Martins on Managing Toxicities Associated With Lenvatinib in DTC
790 viewsFeb 25, 2016
YouTubeOncLive
2:40
Efficacy and Safety of Lenvatinib/Everolimus in mRCC
328 viewsAug 20, 2018
YouTubeTargeted Oncology
See more videos
Static thumbnail place holder